<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342029</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-259-0124 - RWISE</org_study_id>
    <nct_id>NCT01342029</nct_id>
  </id_info>
  <brief_title>Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia</brief_title>
  <acronym>RWISE</acronym>
  <official_title>Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is designed to test the use of ranolazine in patients with angina (chest
      discomfort due to reduced blood supply to the heart) due to microvascular coronary
      dysfunction (MCD; abnormalities in the small blood vessels of the heart). This drug is
      approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina. The
      FDA has approved this drug based on studies primarily on patients with chronic angina with
      major blockages of the arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded, placebo- controlled, and cross-over clinical trial. 147
      subjects will be enrolled at two clinical sites, with projected 9-10% dropout and anticipated
      134 completed subjects. To maintain blinding of the investigators, the study randomization
      table will be kept in Pharmacy Service. The sponsor will ship the study drug directly to the
      Pharmacy Service. The pharmacy service will also be responsible for dispersing the study
      drug.

      There are 4 study visits (2 visits in each study period) in this study. Subjects will be in
      this study for about 6 weeks from Week 0 - baseline visit to Week 6 - exit visit. Besides the
      procedure of study medication mentioned above, other study procedures include informed
      consent, physical exam, questionnaires, EKG for safety assessment, blood collection for
      laboratory testing, cardiac MRI, and follow-up events. In sum, participants will be asked to
      undergo 2 cardiac MRI's and fill out questionnaires 4 times. They will be asked to
      participate for 6 weeks with two 2-week courses (with a treatment window period of 5 days),
      one with ranolazine and the other with placebo (without knowing which they are taking). There
      is a 2-week washout period between treatments. The participants will otherwise remain on all
      their usual medications. The physicians will also be blinded to which medication the subject
      is receiving.

      Participation in this study will be approximately 6 weeks, which consists of two 2-week study
      periods and in between a 2-week washout period:

        1. During the first 2-week period: Subjects will be randomized to first receive either the
           ranolazine or a placebo pill (sugar pill with no active medicine). Subjects will take
           the extended-release ranolazine or a placebo pill for a total of 2 weeks. Subjects will
           take 500 mg twice daily for the first 1 week and then 1000 mg twice daily for an
           additional 1 week. Subjects who are unable to take the higher dose due to side effects
           will remain on 500 mg twice daily for the entire study period. After the 2 weeks, the
           participant will have a Cardiac MRI and complete study questionnaires. These tools will
           allow us to evaluate if the participant is doing better on the medication.

        2. 2-week washout period: Subject will then be asked to go 2 weeks without any study
           medication (ranolazine or placebo).

        3. During the second 2-week period: Subject will then be given either extended release
           ranolazine or placebo depending on which was received the first time for a total of 2
           weeks. Subjects will take 500 mg twice daily for the first 1 week and then 1000 mg twice
           daily for an additional 1 week. Subjects who are unable to take the higher dose due to
           side effects will remain on 500 mg twice daily for entire study period. This 2-week
           period will again be followed by a final Cardiac MRI and questionnaire completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seattle Angina Questionnaire (SAQ)</measure>
    <time_frame>2 weeks (first intervention) and 6 weeks (second intervention)</time_frame>
    <description>Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.
The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and quality of life. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Magnetic Resonance (CMRs)</measure>
    <time_frame>2 weeks (first intervention) and 6 weeks (second intervention)</time_frame>
    <description>Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 2nd week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion reserve index.
Myocardial perfusion reserve index (MPRI) was assessed using the first-pass perfusion intensity curves during stress and rest cardiac magnetic resonance imaging. First-pass perfusion images were analysed using CAAS MRV CMRI analysis software Version 3.3 (Pie Medical Imaging B.V., Maastricht, the Netherlands). Global MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.
Higher MPRI represents better myocardial perfusion reserve. Since MPRI is an index, there is no unit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Microvascular Coronary Dysfunction (MCD)</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.
500-1,000 mg po bid for 2 weeks</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500-1,000 mg po bid for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women age &gt;18 from diverse racial/ethnic groups;

          2. Competent to give informed consent;

          3. Patients with chronic angina or its equivalent;

          4. Coronary angiogram revealing MCD with no obstructive CAD (epicardial coronary stenosis
             &lt;50% luminal diameter stenosis);

          5. Left ventricular ejection fraction &gt; or = 45%;

          6. Objective evidence of ischemia by noninvasive methods such as exercise stress test,
             stress Echo, MRI, or SPECT;

          7. Patients with 10% myocardial ischemia by Cardiac magnetic resonance imaging (CMRI)
             myocardial perfusion reserve index ≤ 2.0 or abnormal coronary reactivity testing (CFR
             &lt; 2.5, or ACH response of no dilation or constriction, determined by local site read).

        Exclusion Criteria:

          1. Acute coronary syndrome (defined by WHO), cardiogenic shock or requiring inotropic or
             intra-aortic balloon support;

          2. Planned percutaneous coronary intervention or CABG or established obstructive CAD with
             ischemia eligible for revascularization, acute MI;

          3. Prior non-cardiac illness with an estimated life expectancy &lt;4 years;

          4. Unable to give informed consent;

          5. Allergy or contra-indication to CMRI testing, including renal failure, claustrophobia,
             and asthma, uncontrolled moderate hypertension (sitting blood pressure &gt;160/95mmHg
             with measurements recorded on at least 2 occasions), conditions likely to influence
             outcomes: Severe lung, creatinine &gt;1.8 or CrCl ≤ 50ml/min) or hepatic disease;

          6. Surgically uncorrected significant congenital or valvular heart disease and other
             disease likely to be fatal or require frequent hospitalization within the next six
             months;

          7. Adherence or retention reasons;

          8. Unwilling to complete follow-up evaluation including repeat testing, documented
             obstructive hypertrophic cardiomyopathy;

          9. Aortic stenosis (valve area &lt;1.5cm);

         10. LV dysfunction (ejection fraction ≤35%);

         11. History of significant cocaine or amphetamine abuse;

         12. Taking potent CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone,
             troleandomycin, clarithromycin, ritonavir, nelfinavir);

         13. Women who are pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Noel Bairey Merz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>127 S. San Vicente Blvd, Suite A9303</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <results_first_submitted>April 21, 2017</results_first_submitted>
  <results_first_submitted_qc>November 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Noel Bairey Merz</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Microvascular Coronary Dysfunction (MCD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine First, Then Placebo</title>
          <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
Ranolazine: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.
500-1,000 mg po bid for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Ranolazine</title>
          <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
Placebo: 500-1,000 mg po bid for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dropout</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dropout</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total 10 dropout (4 dropout during period 1, 4 dropout during washout, 2 dropout during period 2)</population>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine/Placebo</title>
          <description>147 subjects will be enrolled at two clinical sites, with projected 9-10% dropout and anticipated 134 completed subjects.
For Ranolazine first group, subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
For Placebo first group, subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seattle Angina Questionnaire (SAQ)</title>
        <description>Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.
The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and quality of life. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.</description>
        <time_frame>2 weeks (first intervention) and 6 weeks (second intervention)</time_frame>
        <population>Not all participants answered every question in the SAQ, thus the numbers are different for each question.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
Ranolazine: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.
500-1,000 mg po bid for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
Placebo: 500-1,000 mg po bid for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Seattle Angina Questionnaire (SAQ)</title>
          <description>Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.
The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and quality of life. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.</description>
          <population>Not all participants answered every question in the SAQ, thus the numbers are different for each question.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Limitation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.09" spread="23.34"/>
                    <measurement group_id="O2" value="66.7" spread="23.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angina Stability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" spread="26.11"/>
                    <measurement group_id="O2" value="51.17" spread="27.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angina Frequency</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.91" spread="26.09"/>
                    <measurement group_id="O2" value="62.73" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.16" spread="21.23"/>
                    <measurement group_id="O2" value="74.17" spread="21.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of Life</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.05" spread="23.09"/>
                    <measurement group_id="O2" value="54.17" spread="23.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAQ Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.49" spread="19.32"/>
                    <measurement group_id="O2" value="60.97" spread="20.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Magnetic Resonance (CMRs)</title>
        <description>Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 2nd week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion reserve index.
Myocardial perfusion reserve index (MPRI) was assessed using the first-pass perfusion intensity curves during stress and rest cardiac magnetic resonance imaging. First-pass perfusion images were analysed using CAAS MRV CMRI analysis software Version 3.3 (Pie Medical Imaging B.V., Maastricht, the Netherlands). Global MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.
Higher MPRI represents better myocardial perfusion reserve. Since MPRI is an index, there is no unit.</description>
        <time_frame>2 weeks (first intervention) and 6 weeks (second intervention)</time_frame>
        <population>Out of 142 randomized, there were 10 dropouts and 4 missing treatment periods. Therefore 128 was included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo basel...</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>147 subjects with projected 9-10% dropout</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Magnetic Resonance (CMRs)</title>
          <description>Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 2nd week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion reserve index.
Myocardial perfusion reserve index (MPRI) was assessed using the first-pass perfusion intensity curves during stress and rest cardiac magnetic resonance imaging. First-pass perfusion images were analysed using CAAS MRV CMRI analysis software Version 3.3 (Pie Medical Imaging B.V., Maastricht, the Netherlands). Global MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.
Higher MPRI represents better myocardial perfusion reserve. Since MPRI is an index, there is no unit.</description>
          <population>Out of 142 randomized, there were 10 dropouts and 4 missing treatment periods. Therefore 128 was included in analysis</population>
          <units>myocardial perfusion reserve index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.46"/>
                    <measurement group_id="O2" value="1.96" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>The SAEs are based on the publication which represent all SAEs throughout the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
Ranolazine: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.
500-1,000 mg po bid for 2 weeks Placebo: 500-1,000 mg po bid for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
Ranolazine: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.
500-1,000 mg po bid for 2 weeks Placebo: 500-1,000 mg po bid for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>NSTEMI</sub_title>
                <description>Hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chest pain, dizziness, and pre-syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>washout</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Placebo washout</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Excessive Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Palpitations and Afib</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Renal change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Throat pain, swelling and tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arm shaking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>C.Noel Bairey Merz, MD</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>310-423-9680</phone>
      <email>merz@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

